TSX:PRX - Post Discussion
Post by
cabbieJBJ on Mar 28, 2012 7:46am
Final cohort dosed
Protox Completes Dosing of Final Cohort of Patients in Transrectal Study
Wednesday, March 28, 2012
SAN DIEGO, CA and VANCOUVER, BC, March 28, 2012/CNW/ - Protox Therapeutics Inc. ("Protox", TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has completed dosing of all four cohorts of patients in its previously announced transrectal study of PRX302 for the treatment of benign prostatic hyperplasia (BPH).
The primary objective of this study is to gather safety information regarding the transrectal route of administration for the intraprostatic injection of PRX302. There were no safety issues identified by the Independent Data Monitoring Committee based on data for all patients through at least the first 15 days after dosing. Patients will continue to be followed for up to 12 months with the 3 month safety data on all patients expected in Q3 2012.
"We are very pleased to have completed the enrollment of this study according to the timeline, which is an important milestone advancing the PRX302 development program." said Dr. Lars Ekman, Executive Chairman and President of Protox.
https://www.theglobeandmail.com/globe-investor/news-sources/?date=20120328&archive=cnw&slug=C8509
Be the first to comment on this post